Want to see SE:XPC full AI Analyst Report?
XP Chemistries AB (XPC) AI Stock Analysis
XP Chemistries AB
(Nasdaq OMX AB:XPC)
The overall score is very low, driven primarily by severe financial distress. The company is burning through its cash reserves with deeply negative operating and free cash flow, and it has no clear path to profitability. Technical trends reinforce this weakness, with the stock trading below all major moving averages and exhibiting bearish momentum. The debt-free balance sheet provides a temporary buffer but is rapidly eroding. The negative P/E ratio and lack of dividends further confirm the high-risk, speculative nature of the investment.
XP Chemistries AB (XPC) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 53.53M
- Dividend Yield
- ―
- Average Volume (3M)
- 288.74K
- Price to Earnings (P/E)
- -4.4
- Beta (1Y)
- 0.12
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Sweden
- Employees
- 2
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals
XP Chemistries AB Business Overview & Revenue Model
Company Description
As a biotechnology company, XP Chemistries AB specializes in the development and production of forest-derived capsaicin and its related compounds. Its diverse offerings include ingredients for animal nutrition, components for cosmetic formulations, h...
How the Company Makes Money
null
XP Chemistries AB Financial Statement Overview
Summary
Financial performance is critically weak. The income statement shows persistent and deep operating losses with a TTM EBIT margin of -37.5% and declining revenue. The cash flow score is alarmingly low at 12, as the company is burning cash rapidly with negative free cash flow of SEK 12.3 million. The only mitigating factor is a debt-free balance sheet, but equity is eroding. The overall financial health is precarious.
Income Statement
18Very NegativeBalance Sheet
65PositiveCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 320.05K | 327.39K | 283.94K | 663.68K | 1.06M | 279.39K |
| Gross Profit | 116.40K | 127.68K | 328.97K | 335.61K | 488.98K | 149.56K |
| EBITDA | -10.28M | -9.05M | -7.52M | -8.70M | -8.50M | -5.01M |
| Net Income | -9.56M | -8.52M | -7.13M | -8.04M | -7.92M | -4.55M |
Balance Sheet | ||||||
| Total Assets | 33.90M | 38.07M | 22.72M | 27.20M | 30.65M | 34.39M |
| Cash, Cash Equivalents and Short-Term Investments | 9.71M | 15.23M | 2.15M | 7.83M | 15.20M | 21.40M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.77M | 1.13M | 1.16M | 1.51M | 1.58M | 3.09M |
| Stockholders Equity | 32.14M | 36.94M | 21.56M | 25.69M | 29.07M | 31.30M |
Cash Flow | ||||||
| Free Cash Flow | -12.34M | -9.18M | -8.53M | -11.41M | -11.80M | -8.13M |
| Operating Cash Flow | -11.68M | -8.85M | -7.69M | -9.08M | -9.85M | -4.99M |
| Investing Cash Flow | -1.30M | -332.30K | -834.96K | -2.33M | -1.95M | -6.31M |
| Financing Cash Flow | 22.47M | 22.26M | 2.85M | 4.04M | 5.60M | 32.70M |
XP Chemistries AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XPC, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.18, and below the 200-day MA of 0.18, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 75.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XPC.
XP Chemistries AB Peers Comparison
Overall Rating
SE:PCAT65Neutral
SE:IMPC56Neutral
SE:ENZY44Neutral
SE:NEXAM41Neutral
SE:CLBIO39Underperform
SE:XPC38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | SEK 14.87M | 4.56 | ― | ― | -17.14% | 88.76% | |
| 56Neutral | SEK 323.02M | -12.36 | ― | ― | 6.10% | 51.80% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 44Neutral | SEK 551.01M | -12.24 | ― | ― | -2.36% | 23.44% | |
| 41Neutral | SEK 258.28M | -12.35 | -9.37% | ― | -4.57% | -15.20% | |
| 39Underperform | SEK 371.09M | -28.83 | ― | ― | 54.37% | 52.22% | |
| 38Underperform | SEK 53.53M | -4.36 | ― | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:XPC | XP Chemistries AB | 0.17 | -0.06 | -26.72% | |
| SE:NEXAM | Nexam Chemical Holding AB | 2.52 | -0.60 | -19.23% | |
| SE:ENZY | Enzymatica AB | 2.27 | 0.32 | 16.41% | |
| SE:IMPC | Impact Coatings AB | 3.07 | 1.66 | 117.27% | |
| SE:CLBIO | Corline Biomedical AB | 14.20 | -5.75 | -28.82% | |
| SE:PCAT | Photocat A/S | 2.48 | -2.32 | -48.33% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026